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C E L L  B I O L O G Y
Identification of the hyaluronic acid pathway  
as a therapeutic target for facioscapulohumeral 
muscular dystrophy
Alec M. DeSimone1, John Leszyk2, Kathryn R. Wagner3, Charles P. Emerson Jr.1*
Facioscapulohumeral muscular dystrophy (FSHD) is linked to epigenetic derepression of the germline/embryonic 
transcription factor DUX4 in skeletal muscle. However, the etiology of muscle pathology is not fully understood, 
as DUX4 misexpression is not tightly correlated with disease severity. Using a DUX4-inducible cell model, we show 
that multiple DUX4-induced molecular pathologies that have been observed in patient-derived disease models 
are mediated by the signaling molecule hyaluronic acid (HA), which accumulates following DUX4 induction. These 
pathologies include formation of RNA granules, FUS aggregation, DNA damage, caspase activation, and cell 
death. We also observe previously unidentified pathologies including mislocalization of mitochondria and the 
DUX4- and HA-binding protein C1QBP. These pathologies are prevented by 4-methylumbelliferone, an inhibitor 
of HA biosynthesis. Critically, 4-methylumbelliferone does not disrupt DUX4-C1QBP binding and has only a limit-
ed effect on DUX4 transcriptional activity, establishing that HA signaling has a central function in pathology and 
is a target for FSHD therapeutics.
INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent, 
debilitating muscular dystrophy without available treatments that 
arises when DUX4, a gene normally restricted to the germ line, 
mesenchymal stromal cells, and the preimplantation embryo, becomes 
epigenetically derepressed in the skeletal muscle of affected individ-
uals (1–3). The DUX4 protein is a double homeobox transcription 
factor that regulates transcription of a large set of well-defined genes 
(4, 5). While the exact mechanism whereby DUX4 causes muscle 
pathology remains uncertain, the prevailing view is that DUX4 acti-
vates misexpression of an inappropriate genetic program in muscle, 
causing pathology and cell death (1). DUX4 has been shown to be 
toxic when misexpressed in a number of FSHD models (6–12). Cell 
death appears to be p53 dependent and occurs in part via activation 
of caspase-3/7, resulting in apoptosis (6, 8, 9), although recent evidence 
supports the existence of a p53-independent mechanism (13, 14).
The pathways that trigger DUX4-dependent cell death are currently 
under investigation. One possible mechanism is increased oxidative 
stress. Genes that confer resistance to oxidative stress are down-regulated 
in FSHD cells (15), and FSHD subject-derived myoblasts, biopsies, 
and/or DUX4-expressing cells have higher basal levels of oxidative 
stress and reactive oxygen species (ROS) (16, 17). DUX4 expression 
also disrupts additional cellular processes. DUX4- expressing myoblasts 
have differentiation/fusion defects and misregulation of the myogenic 
program (6, 7, 11, 18) [although some of these observations have not 
been confirmed (5, 19)] and distorted morphology (19, 20), and DUX4 
expression is associated with altered cell migration (21). Another 
possibility is that DUX4 binds to or suppresses expression of myo-
genic transcription factors PAX3 and PAX7, which are not detected 
in DUX4-expressing cells, and their overexpression can rescue DUX4 
pathology. Suppression of PAX7 target gene expression has been reported 
as a signature of FSHD muscle (6, 22–24). At the molecular level, subject- 
derived or DUX4- expressing cells also have altered expression of 
spliceosome components and splicing patterns (12), impaired nonsense- 
mediated decay (25), impaired ubiquitination (26), and altered pro-
teomes (18, 27). In addition, specific markers of DUX4-induced 
pathologies include nuclear aggregation of the splicing- and amyotrophic 
lateral sclerosis (ALS)–associated transactive response DNA binding 
protein 43 kDa (TDP-43) and fused in sarcoma (FUS) proteins, dis-
rupted promyelocytic leukemia protein (PML)  bodies and SC35 speckles 
(26, 28), and the appearance of double-stranded RNA (dsRNA) granules 
(14). These disruptions may be a downstream result of misexpression 
of DUX4 target genes, or they may be direct results of interactions with 
cellular proteins, as DUX4 has recently been shown to bind to a wide 
variety of proteins, including the aforementioned FUS protein (29).
To investigate mechanisms underlying of DUX4-induced pathol-
ogies, we conducted a proteomics study in FSHD subject-derived 
cells to identify DUX4-interacting proteins that might place DUX4 
expression within a pathway that mediates its toxicity. We found 
that DUX4 binds C1QBP, an interaction that has also recently been 
identified in a yeast two-hybrid screen (29). C1QBP is regulated 
by the prevalent glycosaminoglycan hyaluronic acid (HA) both 
through direct C1QBP-HA binding and by phosphorylation via an 
HA-dependent signaling pathway (30–32), suggesting a role for 
HA-mediated signaling in DUX4-induced toxicity. To examine this 
possibility, we have used the DUX4-inducible human myoblast cell 
line MB135-DUX4i (33), which has been shown to have molecular 
disease pathologies similar to those reported in patient-derived FSHD 
myogenic cells. Unlike FSHD cells, which sporadically express DUX4 
in a small fraction of nuclei (34, 35), MB135-DUX4i cells can be 
synchronously induced to activate high-level expression of DUX4, 
uniquely enabling molecular investigations of DUX4 pathologies 
under controlled and acute experimental conditions. Using this model, 
we demonstrate that DUX4 expression promotes accumulation of 
HA in DUX4-expressing cells. Furthermore, we show that increased 
HA levels are associated with multiple previously unobserved cellular 
pathologies, including disruption of the normally perinuclear localiza-
tion of C1QBP and the mitochondria, as well as several pathologies that 
1Wellstone Muscular Dystrophy Program, Department of Neurology, University of 
Massachusetts Medical School, Worcester, MA, USA. 2Department of Biochemistry 
and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, 
MA, USA. 3Center for Genetic Muscle Disorders, Kennedy Krieger Institute, Johns 
Hopkins School of Medicine, Baltimore, MD, USA.
*Corresponding author. Email: charles.emersonjr@umassmed.edu
Copyright © 2019 
The Authors, some 
rights reserved; 
exclusive licensee 
American Association 
for the Advancement 
of Science. No claim to 
original U.S. Government 
Works. Distributed 
under a Creative 
Commons Attribution 
NonCommercial 
License 4.0 (CC BY-NC).
 o
n
 January 22, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
DeSimone et al., Sci. Adv. 2019; 5 : eaaw7099     11 December 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
2 of 12
have previously been observed in FSHD-derived cell lines expressing 
endogenous DUX4, including induction of nuclear dsRNA foci, 
FUS aggregation, DNA damage, and cell death. Critically, treatment 
of DUX4-expressing myoblasts with 4-methylumbelliferone 
(4MU), a well-characterized competitive inhibitor of HA biosynthesis 
(36), prevents DUX4-induced accumulation of HA and the induction 
of each of these pathologies, including the activation of caspase-3/7 
and cell death. 4MU treatment prevents these pathologies without 
having an observable impact on DUX4 protein abundance or nuclear 
localization. Our findings therefore establish HA as an essential me-
diator of DUX4 pathology that functions at an early stage in DUX4 
pathogenesis and identify HA synthesis and HA-dependent pathways 
as FSHD therapeutic targets.
RESULTS
DUX4 expression causes pathological accumulation of HA
To identify molecular pathways that mediate DUX4 toxicity, we used 
proteomic coimmunoprecipitation (co-IP) assays and identified 
C1QBP as a DUX4-interacting protein in FSHD subject-derived cell 
lines (data S1). C1QBP has also been identified as a DUX4-binding 
protein in a yeast two-hybrid screen and validated with co-IP and 
HaloTag pull-down systems (29). C1QBP is a promising candidate 
mediator of DUX4 and FSHD pathology because of its functions in 
multiple processes that are disrupted in FSHD muscle and/or in re-
sponse to DUX4 misexpression, both in the nucleus, where it regu-
lates gene expression (37, 38) and RNA splicing [reviewed in (39)], 
and in the mitochondria, where it regulates metabolism (40), ROS 
generation, and cell death/apoptosis (39), and it is also a regulator 
of cell migration (41). C1QBP is also regulated by the signaling mol-
ecule HA, which it can bind to directly, and its function is subject to 
HA-regulated signaling cascades (30–32).
To investigate the role of HA and C1QBP in DUX4-induced cy-
totoxicity, we used the MB135-DUX4i myoblast FSHD model, an 
immortalized myoblast line that has been validated for its FSHD 
biomarker expression and DUX4-induced molecular pathologies. 
This line has been engineered with a doxycycline (DOX)–inducible 
DUX4 transgene, making it uniquely suitable for investigations of 
DUX4-induced molecular pathologies (33). To determine whether 
HA has a role in DUX4-induced pathogenesis, we assayed changes 
in cellular HA levels following DUX4 induction using biotinylated 
HA-binding protein (Fig. 1A). Uninduced cells expressed low levels 
of HA that noticeably increased following DUX4 induction, while 
parental myoblasts that do not contain the DUX4 expression cassette 
did not increase HA expression (fig. S1A). Transcriptome analysis 
(33) and reverse transcription polymerase chain reaction (RT-PCR) 
demonstrated that DUX4 induction caused increased HA synthase 3 
(HAS3) expression in MB135-DUX4i myoblasts, but not in parental 
cells, providing one possible mechanism for the overall increase in 
HA abundance (Fig. 1B and fig. S1B).
We next asked whether increased HA levels have any effect on 
the HA-regulated and DUX4-interacting protein C1QBP. Using 
immunofluorescence assays, we observed that C1QBP is primarily 
localized in the perinuclear region of MB135-DUX4i and parental 
MB135 cells, consistent with mitochondrial localization. Its peri-
nuclear localization was disrupted upon DUX4 induction in MB135- 
DUX4i cells, but not in parental MB135 cells (Fig. 1C and fig. S1C). 
To determine whether C1QBP is being dislocated from the mitochon-
dria, we colabeled cells with C1QBP antibodies and MitoSpy dye 
(Fig. 1D). Under uninduced conditions, robust C1QBP staining oc-
curred almost exclusively within the mitochondria, except for a 
small patch adjacent to nuclei that stained for C1QBP and did not 
costain with MitoSpy (Fig. 1D, top). Under induced conditions, 
both C1QBP and the mitochondria became disorganized, and much 
of its perinuclear staining was lost, although a large fraction of 
C1QBP staining remains colocalized with the mitochondria 
(Fig. 1D, bottom), showing that DUX4 expression also disrupts mito-
chondrial organization. Both C1QBP and the mitochondria remained 
perinuclear in response to DOX induction in parental MB135 control 
cells (fig. S1, C and D). To investigate whether C1QBP mislocalization 
is a secondary response to DUX4-induced activation of caspases 
and apoptosis, we assayed C1QBP localization in DOX-induced MB135- 
DUX4i cells in the presence of the caspase-3/7 inhibitor Z-DEVD- 
FMK. We found that Z-DEVD-FMK inhibited caspase-3/7 activation 
(fig. S2A) and the appearance of condensed, apoptotic chromatin 
(fig. S2B) but did not prevent the mislocalization of C1QBP (Fig. 1E). 
To determine whether mislocalization of C1QBP is an effect of 
DUX4-induced ROS generation, we treated induced cells with the 
antioxidant -mercaptoethanol (ME) at a concentration that in-
hibits DUX4 toxicity (6) and found that ME did not block C1QBP 
mislocalization (fig. S2C), indicating that C1QBP mislocalization is 
not a downstream response to DUX4-induced oxidative stress 
(6, 17). These findings establish that C1QBP dislocation is an early 
response to DUX4 misexpression and identifies C1QBP and mito-
chondrial mislocalization as DUX4 pathologies associated with 
HA production.
To test whether increased HA production is required for C1QBP 
and mitochondrial mislocalization phenotypes, we treated MB135-
DUX4i myoblasts with 4MU, a well-established competitive sub-
strate inhibitor of HA biosynthesis that causes rapid depletion of 
HA (36, 42). We found that 4MU treatment blocked the accumula-
tion of HA in DUX4-induced cells (Fig. 2A) but did not inhibit the 
expression of HAS3 in induced cells (Fig. 2B). Notably, 4MU inhi-
bition of HA production preserved the perinuclear localization of 
C1QBP in DUX4-induced cells but did not affect the expression or 
localization of DUX4 itself, demonstrating that C1QBP mislocalization 
is a downstream response to HA overproduction (Fig. 2C). Similarly, 
4MU treatment preserved mitochondrial localization (Fig. 2D), es-
tablishing that HA is essential for these DUX4-induced pathologies. 
To investigate the possibility that HA mediates these pathologies 
by promoting DUX4-C1QBP physical interaction, we performed 
DUX4-C1QBP co-IP assays on the nuclear fraction of DOX-induced 
MB135-DUX4i myoblasts in the presence and absence of 4MU. Our 
findings show that the DUX4-C1QBP complex is not disrupted in 
response to 4MU depletion of HA (Fig. 2E), suggesting that the critical 
role of HA in DUX4-induced pathology is not to promote to forma-
tion of C1QBP-DUX4 complexes.
Preventing HA production rescues DUX4-induced toxicity
We then investigated whether HA synthesis is required for DUX4- 
induced cytotoxicity. After 24 hours of DUX4 induction and 4MU 
treatment, MB135-DUX4i myoblasts showed a marked dose- 
dependent resistance to cytotoxicity, as evidenced by the reduction 
in the number of rounded and/or detached cells (Fig. 3A). In addi-
tion, while the DUX4-induced cells that remained attached showed 
atypical, jagged morphology, 4MU-treated cells did not show these 
changes, instead maintaining a more normal but somewhat elongated 
shape (likely a result of the absence of secreted HA affecting the 
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Fig. 1. DUX4 expression causes HA accumulation. (A) MB135-DUX4i myoblasts were left untreated or treated with DOX (2 g/ml) for 24 hours and stained with biotinylated 
HA-binding protein (bHABP) and Hoechst dye. Control samples were treated with hyaluronidase (HAase) to show specificity of the biotinylated HA-binding protein stain. 
(B) MB135-DUX4i myoblasts were treated as in (A), and the expression of HAS3 was measured by RT-PCR. The mean ± SEM are indicated. Significance was determined 
using t tests. n = 3. (C) MB135-DUX4i myoblasts were left untreated or treated as in (A) and immunostained with C1QBP and DUX4 antibodies and Hoechst dye. The arrow 
indicates examples of overlapping staining. (D) Myoblasts were treated as in (A) and stained with C1QBP antibodies and MitoSpy and Hoechst dyes. Arrows indicate 
examples of overlapping staining. (E) Myoblasts were either left uninduced or induced with DOX, treated with 30 M Z-DEVD-FMK or dimethyl sulfoxide (DMSO) vehicle, 
and immunostained with C1QBP and DUX4 antibodies and Hoechst dye. Scale bar, 35 m. Inset: 75 m. All experiments were performed a minimum of three times. 
***P < 0.001.
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Fig. 2. C1QBP and mitochondrial pathology depend on HA synthesis. (A) MB135-DUX4i myoblasts were left uninduced or induced with DOX, simultaneously treated 
with 1 mM 4MU or 1% DMSO vehicle for 24 hours, and stained with biotinylated HA-binding protein and Hoechst dye as in Fig. 1. (B) HAS3 expression was measured by 
RT-PCR in uninduced or 24 hour–induced myoblasts treated with 2 mM 4MU or an equal volume of DMSO vehicle. The means ± SEM are indicated. Significance was de-
termined using t tests with multiple hypothesis correction using the Bonferroni-Dunn method. n = 3. (C) Myoblasts were induced, treated with 4MU or DMSO vehicle as 
in (A), and stained for C1QBP and DUX4 as in Fig. 1C. The arrow indicates examples of overlapping staining. (D) Cells were treated as in (C) and stained for C1QBP and 
mitochondria as in Fig. 1B. Arrows indicate examples of overlapping staining. Scale bar, 35 m. Inset: 75 m. (E) MB135-DUX4i myoblasts were either left uninduced or induced 
and treated with the indicated compounds as above. Immunoprecipitations (IP) were performed from nuclear lysates using either DUX4 antibodies or isotype- matched control 
antibodies, and DUX4 and C1QBP were analyzed by immunoblotting (IB). All experiments were performed a minimum of three times. ***P < 0.001, n.s., not significant.
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Fig. 3. DUX4-induced toxicity requires HA. (A) Myoblasts were left untreated, treated with DOX (2 g/ml) alone, 1 mM 4MU alone, or DOX (2 g/ml) plus the indicated 
concentration of 4MU or DMSO for 24 hours and were imaged by phase-contrast microscopy. Experiments were performed three times. (B) Representative scatterplots 
of flow cytometry experiments. Cells were treated as in (A) and were then stained for caspase-3/7 activation and cell death using the CellEvent Assay Kit. (C) Left: The total 
fraction of caspase-3/7–activated cells (quadrants 1 and 2) from three independent experiments was plotted against the concentration of 4MU used and fitted to a linear 
trend line. Data points from individual experiments are indicated with dots. n = 3. Right: The fraction of caspase-3/7–activated cells from induced myoblasts treated with 
1 mM 4MU plotted against induced myoblasts treated with an equal volume (1%) of DMSO. Values from individual experiments are indicated with dots. The means ± SEM 
are indicated. n = 3. (D) Left: As in (C), with the total fraction of live cells (quadrant 4) plotted against the concentration of 4MU and fitted to a second-degree polynomial 
trend line. Right: The fraction of live cells from induced cultures treated with 1 mM 4MU plotted against induced cultures treated with an equal volume (1%) of DMSO. Data 
points, mean, and SEM are indicated as in (C). Significance was determined using Welch’s t tests. n = 3. Scale bar, 100 m *P < 0.05, **P < 0.01, and ***P < 0.001.
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ability of the cells to attach to the plate). Single-dose treatment with 
4MU also provided dose-dependent inhibition of toxicity at 36 and 
48 hours following induction (fig. S3, A and B), although less pro-
tection was observed at these later time points.
To quantitate the extent of protection that 4MU provides against 
DUX4-induced toxicity, we used the CellEvent Caspase-3/7 Green 
Flow Cytometry assay, which measures caspase-3/7 activation and 
cell permeability to SYTOX stain, a marker of cell death (Fig. 3B). 
Uninduced cells could be grouped into two distinct populations. 
Most uninduced cells were negative for both caspase-3/7 activation 
and SYTOX, reflecting a population of mostly live, nonapoptotic cells. 
The uninduced cultures also contained a small population of SYTOX- 
stained, likely necrotic, cells. By contrast, after 24 hours of induction, cells 
could be assigned to three distinct populations. While many cells 
remained negative for both caspase-3/7 activation and SYTOX, DOX- 
induced cultures also contained populations of caspase-3/7–positive cells, 
as well as a caspase-3/7– and SYTOX double-positive populations. 
Critically, 2 mM 4MU treatment maintained DOX- induced cultures 
at low levels of caspase-3/7 and SYTOX staining that were similar 
to uninduced control cultures, and 4MU inhibition of cell death was 
dose dependent, as seen in plots of 4MU concentration against the total 
fraction of caspase-3/7–positive cells (quadrants 1 and 2 of the scatterplots) 
(Fig. 3C, left) or the fraction of live cells (quadrant 4) (Fig. 3D, left). 
Results were statistically significant compared to the vehicle control 
(Fig. 3, C and D, right), which did not affect toxicity, although higher 
doses of dimethyl sulfoxide (DMSO) had a protective effect (fig. S3, 
C and D). These results show that preventing DUX4-induced HA accu-
mulation by treatment with 4MU protects cells from the proapoptotic/
pro-cell death effects of DUX4 expression, further establishing an 
essential role for HA as an effector of DUX4-induced cytotoxicity.
4MU blocks DUX4-mediated nuclear pathologies
In addition to DUX4-mediated cell death, a number of DUX4- 
induced nuclear pathologies have been observed in patient-derived 
cells expressing endogenous levels of DUX4, suggesting that they 
are highly relevant to DUX4-induced muscle disease. These include 
the induction of dsRNA foci, which have been proposed to activate 
a toxic innate immunity response (14), the misregulation of the 
ALS-associated nuclear protein FUS into large aggregates and dis-
creet foci (28), and the accumulation of DNA damage (16, 43). To 
determine whether HA signaling is important to these pathologies, 
we used immunostaining assays and 4MU to investigate their de-
pendence on HA. Using the K1 antibody, which specifically recognizes 
dsRNA foci, we found that inducing cells with DOX led to the 
appearance of these dsRNA foci in MB135-DUX4i myoblasts 
(Fig. 4A), but not in parental myoblasts (fig. S4A). The appearance 
of these foci was blocked by 4MU (Fig. 4A), showing that DUX4- 
induced dsRNA granule formation is dependent on HA accumulation. 
To determine whether the HA requirement is specific to DUX4 
pathology or a general requirement of HA for foci formation, we 
induced dsRNA foci by transfection of myoblasts with polyinosinic: 
polycytidylic acid [poly(I:C)], followed by treatment with 4MU or 
vehicle control, and we found that 4MU did not block poly(I:C) in-
duction of dsRNA foci (Fig. 4B). These findings establish that the 
requirement for HA synthesis in foci formation is specific to DUX4- 
induced foci and unrelated to the downstream process of foci formation.
We next investigated the effect of 4MU on the DUX4-induced 
redistribution of the FUS protein (28). After 24 hours of induction, 
we observed DUX4-specific appearance of dysregulated FUS in the 
form of uneven/aggregated staining, discreet foci, and low-level 
staining, but this was not observed in parental cells (Fig. 4A and 
figs. S4B and S5). 4MU treatment reduced the prevalence of these 
disruptions (Fig. 4A and fig. S5). Unexpectedly, we observed that 
FUS foci often colocalized with dsRNA foci. We quantitated these 
observations by counting the fraction of nuclei containing at least one 
dsRNA focus and the fraction of dsRNA foci that colocalize with a 
FUS aggregate,and found that approximately 1 in 10 DUX4-induced 
nuclei contained dsRNA foci and that approximately three-fourths 
of dsRNA foci colocalize with a FUS aggregate, suggesting that these 
nuclear body structures arise as part of a common pathological process 
that depends on HA (Fig. 4, C and D).
The unexpected accumulation of dsRNA and FUS into coaggregates 
in response to DUX4 induction prompted us to investigate whether 
these granules are associated with double-stranded DNA (dsDNA) 
breaks, as both FUS and dsRNA have been associated with DNA 
repair (44, 45), and DUX4 expression is known to cause DNA damage in 
FSHD subject-derived cells (16, 43). To assay DNA repair, MB135-
DUX4i myoblasts were costained with either dsRNA or FUS anti-
bodies and with antibodies to H2A.X, a histone variant that is a 
nuclear marker for dsDNA break repair (46). We observed increased 
H2A.X staining in response to DOX induction in MB135-DUX4i 
myoblasts, but not in parental myoblasts (Fig. 5A and fig. S4C). 
H2A.X staining was reduced in the presence of 4MU, further sup-
porting a requirement for HA in DUX4 DNA damage pathology. 
Both dsRNA foci (Fig. 5A) and FUS aggregates (fig. S5A) frequently 
colocalized with H2A.X foci. We quantitated the fraction of nuclei 
with dsRNA foci (Fig. 5B) and the fraction of foci colocalizing with 
H2A.X (Fig. 5C) and found that greater than half of dsRNA foci 
were associated with a H2A.X foci, consistent with a role for these 
foci in DNA damage repair. Unexpectedly, however, these dsRNA/
FUS/H2A.X foci do not arise purely in response to DNA damage, 
as DNA damage induced by either hydrogen peroxide or etoposide 
did not promote dsRNA foci formation (Fig. 5, D and E, and fig. S6, 
A and B). These findings establish that dsRNA foci are induced by a 
DUX4-dependent mechanism independent of DNA damage and 
repair. Similarly, treating induced cells with high concentrations of 
ME to reduce oxidative stress had only a minimal impact on the 
number of DUX4-induced dsRNA foci (fig. S7), further validating 
the conclusion that dsRNA foci formation is a direct response to DUX4. 
We also observed that 4MU treatment of DUX4-induced myoblasts 
reduced H2A.X staining in immunofluorescence assays (Fig. 5A), 
indicating that DNA damage is an additional DUX4-induced pathology 
dependent on HA. To validate this finding, we quantitated H2A.X 
levels in induced MB135-DUX4i myoblasts by flow cytometry and 
found that 1 mM 4MU reduced the fraction of myoblasts with dsDNA 
breaks relative to untreated or vehicle-treated myoblasts (Fig. 5F 
and fig. S6C), supporting our previous findings that HA is essential 
for DUX4-induced DNA damage.
HA is not essential for DUX4 transcriptional activity
DUX4-induced pathologies have been proposed to depend on its 
transcriptional function, as mutations to either its DNA binding 
domains or its C-terminal domain ablate much of its toxicity 
(8, 10, 22). To clarify the role of DUX4-induced transcription in 
toxicity, we treated either uninduced control or induced MB135-
DUX4i myoblasts with 4MU and assayed the expression of C1QBP 
and seven validated DUX4 target genes using RT-PCR (Fig. 6). In 
uninduced cells, 4MU had an inhibitory effect on the expression of 
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C1QBP and the basal expression of DUX4 target genes. In DUX4-induced 
myoblasts, 2 mM 4MU selectively inhibited target gene expression. 
Some targets (LEUTX, KHDC1, and MBD3L2) showed considerable 
inhibitory effects, while others showed little or no effect (TRIM43 
and ZSCAN4), and others showed intermediate effects (PRAMEF1 and 
PRAMEF2). Even the most 4MU-affected genes were still robustly 
induced relative to their expression in uninduced cells, even at a high 
4MU concentration that completely blocked DUX4-induced cyto-
toxicity (Fig. 3). These findings establish that 4MU can partially uncouple 
DUX4 transcriptional activity from DUX4-induced pathology, suggesting 
that DUX4 toxicity is mediated either by a transcription independent 
mechanism or by a smaller subset of critical DUX4-regulated genes 
that mediate its toxicity by activating HA-dependent pathways.
DISCUSSION
In this study we have investigated molecular pathways of DUX4 
toxicity using the DUX4-inducible MB135-DUX4i cell model of 
FSHD pathology (33). We observed a number of previously un-
identified molecular pathologies that arise from expression of 
DUX4 in myogenic cells, including changes in localization of the 
DUX4- and HA-binding protein C1QBP, and misregulation of 
the mitochondria. We also observed that DUX4 expression induces 
aberrant accumulation of HA, possibly by increasing expression of 
the HA-producing gene HAS3 (33) [although the role of HAS3 re-
mains unclear, as virally induced expression of DUX4 in myoblasts 
led to only a mild up-regulation of HAS3 expression (33) and HAS3 
up-regulation was not observed in DUX4-expressing myotubes 
(12, 33)]. However, 4MU inhibition of HA synthesis prevents these 
pathologies, including DUX4- induced pathologies that have been 
previously observed in FSHD patient cells expressing endogenous 
levels of DUX4, validating the relevance of these observations to FSHD 
pathology. Last, we show that inhibiting HA synthesis has little effect 
on activation of DUX4 target genes or the DUX4-C1QBP complex, 
which establishes that HA signaling plays an essential role in me-
diating DUX4-induced pathology.
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Fig. 4. Nuclear DUX4-induced pathologies are dependent on HA. (A) MB135-DUX4i myoblasts were treated with the indicated compounds for 24 hours and stained 
with antibodies against dsRNA and FUS and with Hoechst dye. (B) Myoblasts were transfected with 0.25 g of poly(I:C) followed by exposure to the indicated compounds 
for 13 hours and were then stained with dsRNA antibodies and Hoechst dye. Experiments were performed four times. (C) The fraction of nuclei containing at least one 
dsRNA focus was quantified. Significance was determined using Welch’s t tests with multiple hypothesis correction using the Bonferroni-Dunn method. n = 3. (D) The 
fraction of dsRNA foci colocalizing with FUS aggregates was quantified. Values from individual experiments are indicated with dots, and bars indicate the mean of experiments ± SDs. 
A total of 718 uninduced, 650 induced, 859 induced, 4MU-treated, and 696 induced, ethanol-treated cells were counted among three independent experiments. A total 
of 290 and 188 dsRNA foci were counted in induced and induced, ethanol-treated cells, respectively. Scale bar, 35 m. Inset: 75 m. *P < 0.05.
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While the precise molecular mechanisms underlying the role of 
HA in pathology are not yet known, our findings establish that HA 
has an essential role in DUX4-induced pathology. Inhibition of HA 
synthesis protects against a diverse array of DUX4-induced pathologies, 
including disruptions of both nuclear and mitochondrial processes. 
The observation that these disparate DUX4-dependent pathologies 
are profoundly inhibited by 4MU indicates that HA acts at a very 
early step in pathogenesis. An attractive possibility is that HA activates 
inappropriate signaling pathways that may be toxic to myogenic cells. 
A second possibility is that HA promotes pathology by directly inter-
acting with protein factors. C1QBP is likely one such HA-binding 
protein, as it regulates several nuclear and mitochondrial activities 
affected by DUX4 (37–40), binds DUX4 [this study and (29)], is an 
HA-binding/HA-regulated protein (30–32), and becomes dysregulated 
in DUX4-expressing cells. However, co-IP studies eliminate the 
possibility that HA is necessary for DUX4-C1QBP binding (Fig. 2E). 
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with bars. For (C), means and SDs are shown. Significance was determined using Welch’s t tests. n = 3. All experiments were performed at least three times. Scale bar, 
35 m. Inset: 75 m. *P < 0.05 and **P < 0.01.
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Alternatively, HA may regulate other functions of C1QBP, or HA 
signal transduction pathways may mediate pathology. C1QBP also 
binds to the closely related DUX4c transcription factor (29), which 
is more widely expressed than DUX4 and is also up-regulated in 
FSHD (47), providing a second avenue for changes in HA concentration 
to trigger pathogenic processes. Thus, by modulating the function 
of DUX4 and/or DUX4c transcription factors, it is possible that changes 
in HA abundance may feedback on C1QBP activity, resulting in further 
perturbation of gene expression or splicing isoform usage. Molecular 
and biochemical studies of C1QBP that discriminate between these 
possibilities will be needed to clarify its function as a mediator of the 
pathological role of HA and as a target for FSHD drug development.
The dependence of DUX4-induced pathology on HA makes its 
biosynthesis and/or HA-dependent signaling pathways critical targets 
for the development of FSHD therapeutics. 4MU itself is a potential 
FSHD therapeutic, as it is an approved drug in Europe for an un-
related indication [reviewed in (36)]. 4MU applications for FSHD 
will require animal model studies to evaluate its known effects on 
myogenesis (42)], which are now feasible (48) and will be an im-
portant next step. An alternative to inhibiting the production of HA 
pharmacologically is targeting the HA synthase enzymes, including 
HAS3, for silencing with antisense oligonucleotide– based approaches 
combined with adenoviral or chemical delivery systems that target 
skeletal muscle. In addition, several well-studied signal transduction 
cascades are induced in response to HA, including RAS phosphorylation, 
phosphatidylinositol 3-kinase/pyruvate dehydrogenase kinase 1/Akt, 
and nuclear factor B pathways, among others (49). Determining 
whether these pathways play a role in toxicity may provide additional 
targets for FSHD therapeutic development.
MATERIALS AND METHODS
Cell culture
The inducible DUX4 myoblast model MB135-DUX4i and its parental 
cells (33) were provided by S. Tapscott. The line was routinely tested for 
mycoplasma contamination by the provider. We confirmed identity 
by ability to induce DUX4 expression and ability to form myotubes 
and confirmed that it is not present in the Register of Misidentified 
Cell Lines. 15ABicCT, 15BBicCT, and 15VBicCT immortalized 
human myoblasts were provided by W. E. Wright (50). We confirmed their 
identity by confirming their ability to form myotubes and by the 
induction of DUX4 target genes in appropriate cell lines after formation 
of myotubes, and they were not present in the Register of Misidentified 
Cell Lines. We confirmed that all five lines are free of mycoplasma con-
tamination. All cells were grown on vessels precoated with 0.1% gelatin 
(G939, Sigma-Aldrich). MB135-DUX4i and parental myoblasts were 
propagated in 20% characterized fetal bovine serum (FBS; SH30071.03, 
Hyclone), dexamethasome (51 ng/ml; D2915, Sigma-Aldrich), fibro-
blast growth factor-basic (bFGF, 10 ng/ml; GF003AF-MG, EMD 
Millipore), and 1× antibiotics/antimycotics (30-004-CI, Corning) in 
Ham’s F10 medium (10-070-CV, Corning). 4MU (M1381, Sigma-Aldrich) 
was diluted in the appropriate culture media from a 100 mM stock in 
DMSO or 100% ethanol. DUX4 was induced by adding doxycycline 
(DOX) hyclate (D9891, Sigma- Aldrich) to 2 g/ml from a stock (2 mg/ml) 
in water. H2O2 (216763, Sigma-Aldrich), ME in phosphate-buffered 
saline (PBS; 2020-05-30, Gibco/Life Technologies), and etoposide were 
added to the media at the concentrations indicated. These immortalized, 
patient- derived myoblasts were grown in medium consisting of 15% 
characterized FBS, zinc sulfate (0.3 g/ml; Z0251, Sigma-Aldrich), vitamin 
B12 (1.4 g/ml; V2876, Sigma-Aldrich), dexamethasome (3.5 to 54 ng/ml; 
D2915, Sigma-Aldrich), human hepatocyte growth factor (2.5 ng/ml; 
130-093-872, Miltenyi Biotec), bFGF (10 ng/ml), 1× antibiotics/
antimycotics (30-004-CI, Corning), and 20 mM Hepes (25-060-Cl, 
Corning) in medium X [4:1 mixture of Dulbecco’s modified Eagle’s 
medium:Medium 199 (10-013-CV and 10-060-CV, Corning)].
Transfections
Plasmid and poly(I:C) transfections were performed using minor 
modifications to the manufacturer’s protocol. One hour before 
transfection, fresh medium was added to cells. Plasmid or High 
Molecular Weight poly(I:C) (tlrl-pic, InvivoGen) and Lipofectamine 
2000 (11668027, Thermo Fisher Scientific) were diluted separately 
into Opti-MEM, vortexed briefly, and incubated at room temperature 
for 5 min. The two solutions were mixed, vortexed briefly, and in-
cubated at room temperature for 20 min. Complexes were added 
dropwise to cells and placed in the incubator for 5 hours. Medium 
was then replaced with medium containing the indicated compounds.
Gene expression analysis
RNA was extracted using an RNeasy Mini Kit (74106, Qiagen) 
according to the manufacturer’s instructions, with QIAshredder 
homogenization and on-column deoxyribonuclease I digestion. Com-
plementary DNA (cDNA) was synthesized using up to 1 g of RNA 
and a SuperScript III First-Strand synthesis kit (18080-051, Invitrogen). 
Reactions were double-primed with oligo dT and random hexamers, 
but otherwise the manufacturer’s protocol was followed, and the 
optional ribonuclease H digestion was included. Real-time PCR was 
performed on approximately 30 ng of cDNA using an iQ SYBR 
Green SuperMix (170-8882, Bio-Rad) and a Bio-Rad CFX96 Real- 
Time System with the following program: 20-l volume, 105°C lid 
temperature, 95°C initial denaturation for 2 min, followed by 
40 cycles of 95°C for 5 s, 60°C for 30 s, and data collection, and then 
a final 65°C extension for 31 s, and a melt curve was produced. 
PCRs were normalized to RPL13A. All reactions yielded single-peak 
melt curves, confirming specificity. Amplification was sufficiently 
efficient to enable analysis of the PCR data using the Ct method. 
Primers were obtained from the references listed in table S2 or 
PrimerBank (https://pga.mgh.harvard.edu/primerbank/) (51, 52).
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Fig. 6. Effects of HA depletion on DUX4 transcriptional Activity. Uninduced or 
induced MB135-DUX4i myoblasts were treated with 2 mM 4MU or 2% DMSO for 
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Fluorescence microscopy
Immunofluorescence assays were performed on cells grown on four- 
chamber slides (Lab-Tek Chamber Slide, 177437, Thermo Fisher 
Scientific) according to assay-specific protocols. Cells were washed 
with PBS and fixed with 2 to 4% paraformaldehyde solution for 10 min 
with agitation at room temperature. Slides were washed three times 
each for at least 3 min with PBS and permeablized for 15 min with 
PBS/0.1% Trition X-100 with agitation at room temperature. Cells 
were then blocked for at least 20 min at room temperature or over-
night at 4°C with 2% blocking solution [2% horse serum (Gibco), 
2% goat serum (Gibco), 2% bovine serum albumin (BSA; A9647-500G, 
Sigma-Aldrich), 0.2% Triton X-100 (A16046, Alfa Aesar), and PBS to 
volume] with agitation at room temperature and were then probed 
overnight with antibodies specific to C1QBP (1:300; A302-862A, Bethyl 
Laboratories), DUX4 (1:50; clone P4H7, a gift from S. Tapscott), 
FUS (1:500; A300-293A, Bethyl Laboratories), dsRNA [1:300; 
SCICONS K1, English and Scientific Consulting, Hungary (SCICONS)], 
or H2A.X (1:500; 05-636, Millipore) at 4°C with agitation. The following 
day, the cells were washed three times for at least 3 min each with 
PBS and were then incubated with a 1:300 dilution of an appropriate 
Alexa Fluor–conjugated secondary antibody (A11017, A11071, A11001, 
A21131, or A21123; Life Technologies) for at least 2 hours at room 
temperature with agitation. Cells were then incubated with Hoechst 
dye (1 g/ml; B2261, Sigma-Aldrich) for at least 10 min at room 
temperature with agitation. Washes were repeated, and coverslips 
were mounted using Fluoro-Gel with tris (17985-11, Electron 
Microscopy Sciences). For HA immunofluorescence, cells were treated 
as above with the following modifications: Following the blocking 
step, hyaluronidase (HAase; ~4000 U/ml) from bovine testes (H3506, 
Sigma-Aldrich) in buffer [20 mM sodium phosphate buffer (pH 7.0), 
77 mM NaCl, and 0.01% BSA] was diluted 1:10 in PBS for a final con-
centration of ~400 U/ml. Cells were in incubated in this HAase solution 
for 3 hours at 37°C with agitation. Cells were then washed in PBS and 
incubated in biotinylated HA-binding protein (10 g/ml; 385911, 
Millipore/Sigma) diluted in PBS for 1 hour with agitation. Alexa Fluor 
594–conjugated streptavidin (1:300; S32356, Life Technologies) was 
used in place of secondary antibody. For mitochondrial staining 
experiments, live cells were stained with 500 nM MitoSpy Orange 
CMTMRos (424803, BioLegend), washed with PBS, and then fixed 
and either washed and imaged immediately or immunostained as above. 
Images were collected using a Leica Microsystems DMR fluorescence 
microscope. For quantitative/cell counting experiments, randomness 
was ensured by viewing fields using phase-contrast optics and then 
switching to the relevant fluorescence optics. Nucleus and protein 
aggregate/distribution counts were determined by visual counts.
Cell death/apoptosis assays
To visualize DUX4-induced cell death, ~1.2 × 105 to 1.25 × 105 cells 
were plated on each well of a 12-well plate (353043, Falcon). The 
following day, the medium was replaced with medium containing 
the indicated compounds. After the indicated exposure time, cultures 
were visualized by phase-contrast microscopy using a Nikon Eclipse 
TS100 microscope.
To visualize caspase-3/7 activation, 5 × 104 cells per well were plated 
on four-chambered slides in 0.6 ml of media with or without DOX and 
either 30 M InSolution Caspase-3 Inhibitor II (Z-DEVD- FMK; 
264156, EMD/Millipore) or an equal volume of DMSO vehicle. After 23 
hours, cells were stained by adding either two drops of ReadyProbes 
CellEvent Caspase-3/7 Green reagent (R37111, Invitrogen) per well 
or Hoechst dye (1 g/ml), and the cultures were placed in the incubator for 
1 hour. Cells were then imaged on a Nikon Eclipse TS100 microscope.
To quantitate apoptosis and cell death, 1.75 × 105 cells per well 
were plated on six-well plates. The next day, medium was replaced 
with medium containing the indicated compounds. After 24 hours, 
the medium was transferred to a 15-ml centrifuge tube. Wells were 
rinsed with PBS, which was transferred to the same tubes. Cells were 
then trypsinized with TrypLE Express (12605-010, Gibco), and re-
actions were stopped with an equal volume of media and added to 
the tubes. Wells were rinsed with PBS, which was also added to the 
tubes. The tubes were spun at ~400g for 5 min. The medium was 
removed, and the cells were suspended in PBS and then added to 
5-ml flow cytometry tubes by passing through a 40-m nylon strainer 
(352340, Falcon). Cells were then stained using the CellEvent 
Caspase-3/7 Green Flow Cytometry Assay Kit (C10427, Invitrogen) 
according to the manufacturer’s instructions, with minor adjustments 
for volume. Flow cytometry was performed using a BD FACSCalibur 
instrument, and the data were analyzed using FlowJo software.
dsDNA break assay
dsDNA breaks were measured using the EMD/Millipore H2A.X 
Phosphorylation Assay Kit (17-344), according to the manufacturer’s 
instructions with minor modifications for volume. Briefly, 1.75 × 
105 MB135-DUX4i myoblasts were plated per well on six-well plates. 
The following day, the test compounds were added to the indicated 
concentrations. After 24 hours, the medium was transferred to 15-ml 
centrifuge tubes. Wells were rinsed with PBS, which was added to 
the centrifuge tubes. The cells were then trypsinized with TrypLE 
Express, and reactions were stopped with an equal volume of media 
and added to the tubes. Wells were washed with PBS, which was also 
added to the tubes. The tubes were then spun down at ~750g for 
5 min and were washed three times with PBS. Cells were resuspended 
in 25 l of fixation buffer and left on ice for 20 min. Fixed cells were 
spun down at ~10,000g and washed twice in PBS and then resuspended 
in 25 l of permeablization buffer. Fluorescein isothiocyanate– 
conjugated antibody (1.75 l) was then added, mixed, and left on ice 
for 20 min. Cells were then diluted with 100 l of wash buffer, spun 
down, washed with Hanks’ balanced salt solution (HBSS; 21-022-CV, 
Corning) and then resuspended in HBSS and transferred into a flow 
cytometry tube by passing through a 40-m nylon strainer. Flow 
cytometry was then performed using a BD LSR II flow cytometer, 
and the data was analyzed using FlowJo software.
Mass spectrometry analysis
Co-IP experiments
Twenty-four hours after transfection with DUX4-expressing plasmids, 
co-IP experiments were performed as described [protocol 2.2 from 
(53)] except that lysis buffers were supplemented with protease 
inhibitor cocktail (2 l/ml; P8340, Sigma-Aldrich). Cytoplasmic lysates 
were made with Tween 20 lysis buffer containing 25 mM tris-HCl 
(pH 8), 25 mM NaCl, 2 mM EDTA, 1 mM phenylmethylsulfonyl 
fluoride, and 0.5% Tween 20, and nuclear lysates were made with 
the same buffer containing 500 mM NaCl. Lysates were precleared 
with 2.5 g of mouse immunoglobulin G (IgG) isotype control 
antibody (5415S, Cell Signaling Technology) and 30 l of protein G 
Agarose beads (11719416001, Roche), and immunoprecipitation 
was performed with 15 l of anti–DUX4 C-2 antibody (sc-376490, 
Santa Cruz Biotechnology) and 30 l of Protein G Agarose beads 
(11719416001, Roche). Samples were boiled in 2X sample buffer [100 mM 
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tris, SDS (40 mg/ml), 20% glycerol, and 100 mM dithiothreitol] and 
were partially separated by polyacrylamide gel electrophoresis for about 
2 cm into the gel. The gel was then stained with Imperial Protein Stain 
(24615, Thermo Fisher Scientific) according to the manufacturer’s 
instructions. Lanes were then cut from the gel and submitted to the 
University of Massachusetts Medical School Proteomics core facility for 
analysis by mass spectrometry. Specific coimmunoprecipitating proteins 
were determined by enrichment of the product in pCI-Neo-DUX4 
(4)–transfected myoblasts relative to pcDNA3.1-transfected 15ABicCT, 
15BBicCT, or 15VBicCT myoblasts.
Sample preparation for mass spectrometry, 
liquid chromatography–tandem mass spectrometry 
analysis, and data analysis
Gel bands were cut into 1 mm by 1 mm pieces and placed in 1.5-ml 
Eppendorf tubes with 1 ml of water for 30 min. Samples were then 
prepared for mass spectrometry, and liquid chromatography–tandem 
mass spectrometry analysis was performed essentially as described 
(54). Data analysis was also performed as described except that raw 
data files were peak-processed with Proteome Discoverer (version 2.0, 
Thermo Fisher Scientific) before database searching with Mascot Server 
(version 2.4) against the Swissprot_Human database.
Co-IP/Western blot analysis
Nuclear lysates were prepared as for co-IP/mass spectrometry analysis 
except that lysates were precleared with 5 g of mouse IgG1 isotype 
control (02-6100, Thermo Fisher Scientific), and precipitations were 
performed with 4 g of anti-DUX4 C-2 antibody or 4 g of isotype 
control. Western blots were performed by separating samples on 
12% Bolt Bis-Tris Plus precast gels (no. NW00122BOX, Thermo 
Fisher Scientific) in Mops buffer (NP0001-02, Invitrogen), transferring 
to polyvinylidene difluoride membranes, and probing according to 
standard methods. Blots were probed with 1:1000 dilutions of anti- 
C1QBP (A302-862A, Bethyl Laboratories) or anti-DUX4 clone E5-5 
(ab124699, Abcam) antibodies, and enhanced chemiluminesence 
was performed using a mouse anti-rabbit–horseradish peroxidase 
secondary antibody (31464, Thermo Fisher Scientific), a SuperSignal 
West Femto kit (34094, Thermo Fisher Scientific) and a ChemiDoc 
MP Imaging system.
Statistical analysis
For all data presented in the figures, error bars are SEM except for 
colocalization experiments, where SDs are presented. Significance 
was determined using unpaired t tests for cases where the assumption 
of equal variance was appropriate or unpaired Welch’s t tests where 
equal variance could not be assumed. The method used is indicated 
in each figure legend. Where indicated, P values were corrected for 
multiple hypothesis testing using the Bonferroni-Dunn method. 
Calculations were performed using GraphPad Prism software or 
GraphPad QuickCalcs (www.graphpad.com/quickcalcs/). Analysis 
was performed on the results of three independent experiments, as is 
traditional, except for RT-PCR experiments in Fig. 6, which, because 
of relatively small differences observed in preliminary experiments, 
were instead performed on six independent experiments. For all 
figures, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P ≤ 0.0001.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/12/eaaw7099/DC1
Fig. S1. DOX does not cause pathology in parental myoblasts.
Fig. S2. Inhibition of caspase-3/7 or ROS does not prevent C1QBP mislocalization.
Fig. S3. Compounds can provide resistance to DUX4-induced toxicity.
Fig. S4. DOX does not cause nuclear pathologies in parental myoblasts.
Fig. S5. FUS aggregates localize to sites of dsDNA breaks and are inhibited by 4MU.
Fig. S6. DNA damage does not cause accumulation of dsRNA after 24 hours and depends on 4MU.
Fig. S7. ME does not prevent DUX4-induced appearance of dsRNA foci.
Table S1. Cells used in this study.
Table S2. Primers used in this study.
Data S1. Identification of DUX4 copurifying proteins by mass spectrometry.
View/request a protocol for this paper from Bio-protocol.
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